Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

The neuromodulation developer Saluda Medical announced that it raised $100 million to help bolster the sales of its ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...